Department of Pediatrics, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
School of Dental Medicine, University of Zagreb, Zagreb, Croatia.
J Asthma. 2023 Dec;60(12):2121-2129. doi: 10.1080/02770903.2023.2220795. Epub 2023 Jun 20.
Remission of childhood asthma has not been widely studied. Patients in clinical remission continue to have some degree of bronchial hyperresponsiveness (BHR). The aim of this study was to investigate whether clinical parameters and lung function test are good parameters for discontinuation of inhaled corticosteroids (ICS) in asthmatic children, including patients with persistent BHR, as measured by the methacholine challenge test (MCT).
One year after discontinuation of inhaled corticosteroids (ICS), MCT was performed in a group of 40 asthmatic children to confirm or exclude BHR. In all patients, ICS treatment was discontinued based on the same parameters: symptoms, spirometry, daily PEF, and negative bronchodilator test. After achieving complete asthma control for at least 6 to 12 months, ICS treatment was stepped down and discontinued. Clinical course and spirometry were followed up after ICS discontinuation.
Positive MCT was found in 50% of the patients. There was no statistically significant difference between the positive and negative MCT groups in age at initiation and discontinuation of ICS therapy, duration of ICS therapy, duration of stepping down period, FEV1, and PEF at the time of withdrawal of ICS and one year later. ICS treatment had to be restarted in two patients from the positive MCT group, due to recurrence of asthma symptoms.
Clinical parameters, normal spirometry, daily PEF values, and a negative bronchodilator test are good parameters for discontinuing ICS treatment in asthmatic children, even in patients with persistent BHR. Children should continue to be monitored, as symptoms may recur.
儿童哮喘的缓解尚未得到广泛研究。处于临床缓解期的患者仍存在一定程度的支气管高反应性(BHR)。本研究旨在探讨在接受沙丁胺醇激发试验(MCT)检测存在持续性 BHR 的哮喘儿童中,临床参数和肺功能测试是否可作为停止吸入性皮质激素(ICS)治疗的良好指标。
在停用 ICS 治疗 1 年后,对 40 例哮喘儿童进行 MCT 以确认或排除 BHR。所有患者均根据相同参数(症状、肺量计检查、每日峰值呼气流速[PEF]和支气管扩张剂阴性试验)停用 ICS。在至少 6 至 12 个月完全控制哮喘后,逐步减少并停用 ICS。在停用 ICS 后对临床病程和肺量计检查进行随访。
50%的患者 MCT 阳性。MCT 阳性和阴性组在 ICS 治疗开始和停止年龄、ICS 治疗持续时间、减量阶段持续时间、停用 ICS 时和停用 ICS 1 年后的 FEV1 和 PEF 方面均无统计学差异。在 MCT 阳性组的 2 例患者中,由于哮喘症状复发,不得不重新开始 ICS 治疗。
在哮喘儿童中,临床参数、正常的肺量计检查、每日 PEF 值和支气管扩张剂阴性试验是停止 ICS 治疗的良好指标,即使在存在持续性 BHR 的患者中也是如此。儿童应继续接受监测,因为症状可能会复发。